Moffitt researchers find dual inhibitor may be safer for CLL patients

Moffitt Cancer Center researchers want to learn more about how PI3K inhibitor therapy works with the body’s immune system to determine if there are ways to predict or mitigate associated adverse effects. Their findings were published in the July 14 issue of Blood Advances, a journal of the American Society of Hematology.